Early postmenopausal bone loss in hyperthyroidism


      Objectives: To evaluate the effect of hyperthyroidism on bone in relation to the menopausal state. Methods: Fifty-nine hyperthyroid (HYPER), 40 hypothyroid (HYPO), and 51 control euthyroid (EUTH) women were studied. Bone mineral density (BMD) was assessed by dual X-rays absorptiometry (DXA) at the lumbar spine, and at the femoral neck. A multi-site QUS device evaluated speed of sound (SOS) at the radius (RAD), tibia (TIB), metatarsus (MTR), and phalanx (PLX). Bone markers used were serum bone specific alkaline phosphatase (BSAP) and urinary deoxypyridinoline (DPD). Results: At all sites, SOS was lower in HYPER than in EUTH (RAD P<0.05, TIB P<0.01, MTR P<0.05, PLX P=0.01). The low SOS was only noted at the early postmenopausal period. BMD at the femoral neck but not at the lumbar spine was lower in HYPER as compared to EUTH (P<0.05). Both femoral neck and tibia were the sites with the highest odds ratio for being hyperthyroid (2.3 and 2.04, respectively). There was no correlation between BMD or SOS and FT4, TT3 or duration of hyperthyroidism. BSAP and DPD positively correlated with FT4 and TT3 (P<0.05). Conclusions: This study suggests that hyperthyroidism affects bone mineralization especially during the early postmenopausal period, and the effect is mainly at the cortical bone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mosekilde L
        • Eriksen E.F
        • Charles P
        Effects of thyroid hormone on bone and mineral metabolism.
        Endocrinol. Metab. Clin. North Am. 1990; 19: 35-63
        • Perry H.M
        Thyroid hormones and mineral metabolism.
        in: Peck W Bone and mineral research. 6. Elsevier, Amsterdam1989: 113-137
        • Eriksen E.F
        • Mesoklide L
        • Melsen F
        Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle.
        Bone. 1986; 7: 101-108
        • Ross D.S
        Hyperthyroidism, thyroid hormone therapy and bone.
        Thyroid. 1994; 4: 319-326
        • Meunier P.J
        • S-Bianchi G.G
        • Edouard C.M
        • Bernard J.C
        • Courpron P
        • Vignon G.E
        Bony manifestations of thyrotoxicosis.
        Orthop. Clin. North Am. 1972; 3: 745-774
        • Mosekilde L
        • Melsen F
        • Bagger J.P
        • Myhre-Jensen O
        • Sorensen N.S
        Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.
        Acta Endocrinol. (Copenh.). 1977; 85: 515-525
        • Faber J
        • Galløe A.M
        Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
        Eur. J. Endocrinol. 1994; 130: 350-356
        • Uzzan B
        • Campos J
        • Cucherat M
        • Nony P
        • Boissel P
        • Perret G.Y
        Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
        J. Clin. Endocrinol. Metab. 1996; 81: 4278-4289
        • Njeh C.F
        • Boivin C.M
        • Langton C.M
        The role of ultrasound in the assessment of osteoporosis: a review.
        Osteoporos Int. 1997; 7: 7-22
        • Van Deale P.L.A
        • Burger H
        • De Laet C.E.D.H
        • Pols H.A.P
        Ultrasound measurement of bone.
        Clin. Endocrinol. (Oxf.). 1996; 44: 363-366
        • Gomez Acotto C
        • Schott A.M
        • Hans D
        • Njepomniszeze H
        • Mautalen C.A
        • Meunier P.J
        Hyperthyroidism influences ultrasound bone measurements of the calcaneus.
        J. Bone Miner. Res. 1995; 10: S400
        • Mazess R.B
        • Barden H.S
        T-score differs among skeletal sites.
        Calcif. Tissue Int. 1999; 64: S104
        • Hans D
        • Srivastav S.K
        • Singal C
        • et al.
        Does combining the results from multiple bone sites measured by a new quantitative ultrasound device improve discrimination of hip fracture?.
        J. Bone Miner. Res. 1999; 14: 644-651
        • Hanley J.A
        • McNeil B.J
        The meaning and use of the area under a receiver operating characteristic (ROC) curve.
        Radiology. 1982; 143: 29-36
      1. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. WHO Technical Series 843, Geneva: World Health Organization, 1994.

        • Fraser S.A
        • Anderson J.B
        • Smith D.A
        • Wilson G.M
        Osteoporosis and fractures following thyrotoxicosis.
        Lancet. 1971; 1: 981-983
        • Nielsen H.E
        • Mosekilde L
        • Charles P
        Bone mineral content in hyperthyroid patients after combined medical and surgical treatment.
        Acta Radiol. Oncol. 1979; 18: 122-128
        • Krølner B
        • Jorgensen J.V
        • Nielsen S.P
        Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and antithyroid treatment.
        Clin. Endocrinol. (Oxf.). 1983; 18: 439-446
        • Toh S.H
        • Claunch B.C
        • Brown P.H
        Effect of hyperthyroidism and its treatment on bone mineral content.
        Arch. Intern. Med. 1985; 145: 883-886
        • Rosen C.J
        • Adler R.A
        Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism.
        J. Clin. Endocrinol. Metab. 1992; 75: 1531-1534
        • Wakasugi M
        • Wakao R
        • Tawata M
        • et al.
        Bone mineral density in patients with hyperthyroidism measured by dual energy X-ray absorptiometry.
        Clin. Endocrinol. (Oxf.). 1993; 38: 283-286
        • Diamond T
        • Nery L
        • Hales I
        A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
        J. Clin. Endocrinol. Metab. 1991; 72: 1184-1188
        • Földes J
        • Tarján G
        • Szathmari M
        • Varge F
        • Krasznai I
        • Horvath C.S
        Bone mineral density in patients with endogenous subclinical hyperthyroidism: Is this thyroid status a risk factor for osteoporosis?.
        Clin. Endocrinol. (Oxf.). 1993; 39: 521-527
        • Kung A.W.C
        • Lorentz T
        • Tam S.C.F
        Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
        Clin. Endocrinol. (Oxf.). 1993; 39: 535-540
        • Franklyn J.A
        • Betteridge J
        • Daykin J
        Long-term thyroxin treatment and bone mineral density.
        Lancet. 1992; 340: 9-13
        • Gorres G
        • Kaim A
        • Otte A
        • Gotze M
        • Muller-Brand J
        Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
        Eur. J. Nucl. Med. 1996; 23: 690-692
        • Greenspan S.L
        • Greenspan F.S
        The effect of thyroid hormone on skeletal integrity.
        Ann. Intern. Med. 1999; 130: 750-758
        • Kung A.W
        • Yeung S.S
        Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
        J. Clin. Endocrinol. Metab. 1996; 81: 1232-1236
        • Ribot C
        • Tremollieres F
        • Pouilles J.M
        • Louvet J.P
        Bone mineral density and thyroid hormone therapy.
        Clin. Endocrinol. (Oxf.). 1990; 33: 143-153
        • Aldin E.V
        • Maurer A.H
        • Marks A.D
        • Channick B.J
        Bone mineral density in postmenopausal women treated with L-thyroxine.
        Am. J. Med. 1991; 90: 360-366
        • Suwanwalaikorn S
        • Van Auken M
        • Kang M.I
        • Alex S
        • Braverman L.E
        • Baran D.T
        Site selectivity of osteoblast gene expression response to thyroid hormone localized by in situ hybridization.
        Am. J. Physiol. 1997; 272: E212-217
        • Milne M
        • Kang M.I
        • Quail J.M
        • Baran D.T
        Thyroid hormone excess increases insulin-like growth factor I transcripts in bone cell cultures.
        Endocrinology. 1998; 139: 2527-2534
        • Weiss M
        • Ben-Shlomo A
        • Hagag P
        • Yaniv I
        • Geva D
        Normative speed of sound database of a novel multi-site quantitative bone ultrasound device.
        J. Bone Miner. Res. 1999; 14: S374
        • Calvo M.S
        • Eyre D.R
        • Gundberg C.M
        Molecular basis and clinical application of biological markers of bone turnover.
        Endocrinol. Rev. 1996; 17: 333-368
        • Kleerekoper M
        Extensive personal experience: the clinical evaluation and management of osteoporosis.
        J. Clin. Endocrinol. Metab. 1995; 80: 757-763
        • Nuzzo V
        • Lupoli G
        • Esposito-Del-Puente A
        • et al.
        Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
        Gynecol. Endocrinol. 1998; 12: 333-337
        • Jodar-Gimeno E
        • Munoz-Torres M
        • Escobar-Jimenez F
        • Quesada-Charneco M
        • Luna-del-Castillo J.D
        • Olea N
        Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover.
        Calcif. Tissue Int. 1997; 61: 370-376
        • Langdahl B.L
        • Loft A.G
        • Moller N
        • et al.
        Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?.
        J. Bone Miner. Res. 1997; 12: 78-88
        • Baur D.C
        • Nevitt M.C
        • Ettinger B
        • Stone K
        Low thyrotropin levels are not associated with bone loss in older women: a prospective study.
        J. Clin. Endocrinol. Metab. 1997; 82: 2931-2936
        • Glant D.J
        • McMuldo M.E.T
        • Mole P.A
        • Paterson C.R
        • Davies R.R
        Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis.
        Clin. Endocrinol. (Oxf.). 1993; 39: 529-533